SynthesisMolecular genetics & genomic medicine2025
Prenatal Characterization of Houge-Janssens Syndrome Type 2: A Case Report and Systematic Review of Fetal Phenotypes Associated With PPP2R1A Mutations.
Synthesis in Molecular genetics & genomic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical and Molecular Spectrum ofGenes · 2025Pooled it
- Prenatal Characterization of Houge-Janssens Syndrome Type 2: A Case Report and Systematic Review of Fetal Phenotypes Associated With PPP2R1A Mutations.Molecular genetics & genomic medicine · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHouge-Janssens syndrome type 2 (HJS2, OMIM 616362) is a rare neurodevelopmental disorder caused by pathogenic variants in PPP2R1A, typically characterized postnatally by hypotonia, developmental delay, intellectual disability, and distinctive craniofacial features.
methodsWe describe a 28-year-old pregnant woman referred for increased nuchal translucency (4.4 mm) and high risk on first trimester screening. Noninvasive prenatal testing showed no common aneuploidies. At 23 weeks of gestation, fetal ultrasound revealed ventriculomegaly and suspected partial agenesis of the corpus callosum. Genetic testing included karyotyping, chromosomal microarray analysis (CMA), and trio-based whole exome sequencing (WES).
resultsKaryotype and CMA were normal. WES identified a de novo heterozygous missense variant in PPP2R1A, NM_014225.6: c.548G>A (p.R183Q), classified as pathogenic. Following genetic counseling, the couple elected to terminate the pregnancy. Integrating our findings with 12 previously reported prenatal cases, we conducted a systematic review of fetal phenotypes associated with PPP2R1A variants. The most common features were ventriculomegaly (92%), agenesis or dysgenesis of the corpus callosum (50%), and congenital heart defects (42%).
conclusionWe present the most comprehensive synthesis to date of prenatal phenotypes associated with PPP2R1A-related neurodevelopmental disorders. These findings provide crucial insights into the prenatal spectrum of HJS2 and highlight key sonographic indicators to support early diagnosis and genetic counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.